Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Non-Current Deffered Revenue (2019 - 2025)

Historic Non-Current Deffered Revenue for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $32.1 million.

  • Avidity Biosciences' Non-Current Deffered Revenue fell 2412.39% to $32.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.1 million, marking a year-over-year decrease of 2412.39%. This contributed to the annual value of $38.0 million for FY2024, which is 718.13% down from last year.
  • Latest data reveals that Avidity Biosciences reported Non-Current Deffered Revenue of $32.1 million as of Q3 2025, which was down 2412.39% from $40.0 million recorded in Q2 2025.
  • Avidity Biosciences' Non-Current Deffered Revenue's 5-year high stood at $43.4 million during Q1 2025, with a 5-year trough of $1.2 million in Q4 2022.
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $21.1 million (2021), whereas its average is $22.5 million.
  • As far as peak fluctuations go, Avidity Biosciences' Non-Current Deffered Revenue plummeted by 8109.31% in 2022, and later soared by 321157.89% in 2023.
  • Avidity Biosciences' Non-Current Deffered Revenue (Quarter) stood at $6.5 million in 2021, then tumbled by 81.09% to $1.2 million in 2022, then soared by 3211.58% to $40.9 million in 2023, then dropped by 7.18% to $38.0 million in 2024, then decreased by 15.53% to $32.1 million in 2025.
  • Its Non-Current Deffered Revenue stands at $32.1 million for Q3 2025, versus $40.0 million for Q2 2025 and $43.4 million for Q1 2025.